Skip to main content
. 2016 Oct 4;87(14):1464–1472. doi: 10.1212/WNL.0000000000003169

Figure 3. Median percentage change in T2-hyperintense and T1-hypointense lesion volume in CARE-MS I and CARE-MS II.

Figure 3

Median percentage change from baseline in T2-hyperintense lesion volume in (A) CARE-MS I and (B) CARE-MS II. Median percentage change from baseline in T1-hypointense lesion volume in (C) CARE-MS I and (D) CARE-MS II. CARE-MS = Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis; NS = no significant difference; SC IFN-β-1a = subcutaneous interferon β-1a. *p < 0.05.